These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20591575)

  • 1. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.
    Buckstein R; Yee K; Wells RA;
    Cancer Treat Rev; 2011 Apr; 37(2):160-7. PubMed ID: 20591575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine for the treatment of myelodysplastic syndrome.
    Cataldo VD; Cortes J; Quintás-Cardama A
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
    Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
    J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
    Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
    Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
    Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
    Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
    Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
    Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of myelodysplastic syndromes patients].
    Santini V
    Recenti Prog Med; 2014 Mar; 105(3):127-31. PubMed ID: 24675456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
    Papoutselis M; Douvali E; Papadopoulos V; Spanoudakis E; Margaritis D; Tsatalas C; Kotsianidis I
    Leuk Res; 2014 Feb; 38(2):161-5. PubMed ID: 24239174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
    Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD
    Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.